BioSpace News Archive

Samsung Bioepis Co., Ltd. announced that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a ranibizumab biosimilar candidate, to reference ranibizumab in patients with neovascular age-related macular degeneration.

Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products, further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.

QIAGEN N.V. announced the publication of its Reasoned Position Statement in response to the Offer Document published by Thermo Fisher Scientific Inc earlier.

Octapharma has announced that results from the ProCID study were shared for the first time as a poster presentation during the virtual American Academy of Neurology 2020 annual meeting.

Fulgent Genetics, Inc., a provider of comprehensive genetic testing solutions, announced that its subsidiary, Fulgent Therapeutics, LLC, has received Emergency Use Authorization from the US Food and Drug Administration for its RT-PCR test for the detection of SARS-CoV-2, the virus that causes COVID-19, using upper respiratory specimens.

Oxygen Plus is one of the fortunate small-to-medium sized businesses that experienced a large increase in consumer demand due to the fear surrounding the still mysterious Coronavirus pandemic.

Company will participate in three events at the largest global translation-focused cell and gene therapy meeting

OneOncology, the national network of independent community oncologists, announced a new partnership with The Center for Cancer and Blood Disorders in North Texas as the oncology network expands its footprint in the southwest.

So-Young International Inc., the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, announced its unaudited financial results for the three months ended March 31, 2020.

Clinical evidence shows significant patient radiation reduction with CorPath® GRX Vascular Robotic System